Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck, Modifi
MSD acquires cancer therapeutics developer Modifi Biosciences
MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with preclinical compounds designed to target DNA repair defects in hard-to-treat cancers.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck acquires Modifi Biosciences in $1.3bn cancer therapy deal
The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for pembrolizumab.
Merck acquires Yale-spinout Modifi Bio in $1.3B deal
Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by biopharmaceutical giant Merck & Co. Inc. in a $1.3 billion deal, the companies announced Wednesday.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE: MRK). Modifi Biosciences was formed in 2021 based on technology spun out of Yale University.
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.
Outsourcing-pharma
4h
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...
BioWorld
1d
Modifi acquired by Merck in $1.3B deal
Modifi
Biosciences
Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Workers reject new contract
Settles civil lawsuit
Accused of plagiarism
Oldest person in US dies
Grizzly bear fatally struck
Courthouse attack charges
Court orders new sentence
Timberlake postpones shows
'Tarzan' star Ron Ely dies
DOJ warns Musk's PAC?
Suffers 'debilitating' stroke
911 calls from rally released
Joins Republican Party
$3.9B storm relief proposal
Pneumococcal vax advice
Carbon removal firms report
Seeks WI ballot exit
Existing home sales fall
Wins EU antitrust case
New lead dust standards
NK troops in RU confirmed
Settles hazardous waste suit
DNC office shootings arrest
G7 Ukraine loan advances
Kentucky lawmaker dies
Israel strikes Lebanese city
FDA recalls antidepressant
Bird flu infects 4 in WA
Yelp disables reviews
Biden says lock up Trump
Hashem Safieddine killed
Related topics
Merck
Yale University
DNA
Feedback